FDA approves J&J and Legend’s Carvykti for second-line multiple myeloma
The FDA has expanded the label for Johnson & Johnson and Legend Biotech’s multiple myeloma CAR-T therapy to make it a much earlier treatment option …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
